Every figure in this peptide dosage chart is something a published study administered, with the study named beside it. Where no study exists, the row says so instead of guessing.
The short version
Most peptide dosage charts cite nothing at all. This one names a study for every row. Thirteen rows carry a dose from a human trial. The rest carry animal work, a pilot report, a label, or nothing. An empty row is a finding, not a gap.
The chart below is the summary. Each compound also has its own page, linked from its row, which carries the full protocol and the sample size. We report what was given. We do not turn any of it into instructions.
What published studies administered
| Compound | Best evidence | What was administered | Route | Source |
|---|---|---|---|---|
| Semaglutide | Phase 3 (STEP-1, n=1,961) | 0.25 mg weekly, stepped to 2.4 mg weekly over 16 weeks; 68 weeks | Subcutaneous | Wilding et al., 2021 |
| Tirzepatide | Phase 3 (SURMOUNT-1, n=2,539) | 2.5 mg weekly, stepped 2.5 mg every 4 weeks to 5, 10 or 15 mg; 72 weeks | Subcutaneous | Jastreboff et al., 2022 |
| Retatrutide | Phase 2 (n=338) | 1, 4, 8 or 12 mg weekly, titrated from 2 or 4 mg over about 12 weeks; 48 weeks | Subcutaneous | Jastreboff et al., 2023 |
| Cagrilintide | Phase 2 (n=706) | 0.3, 0.6, 1.2, 2.4 or 4.5 mg weekly, titrated every 4 weeks; 26 weeks | Subcutaneous | Lau et al., 2021 |
| Tesamorelin | Phase 3 (n=412) | 2 mg once daily; 26 weeks | Subcutaneous | Falutz et al., 2007 |
| PT-141 (bremelanotide) | Phase 3 + approved label | 1.75 mg as needed, at least 45 minutes before activity; no more than one dose in 24 hours and no more than 8 a month | Subcutaneous | FDA Vyleesi prescribing information, 2019 |
| CJC-1295 (DAC) | Two ascending-dose trials in healthy adults | Ascending single doses; 30 and 60 µg/kg reported as the best tolerated | Subcutaneous | Teichman et al., 2006 |
| Ipamorelin | Phase 2 (n=114 analyzed) | 0.03 mg/kg twice daily, day 1 until day 7 or discharge; missed its endpoint | Intravenous | Beck et al., 2014 |
| BPC-157 | Two small pilot reports | 10 mg once (n=12); 10 mg on day 1 then 20 mg on day 2 (n=2) | Intravesical; intravenous | Lee et al., 2024; Lee & Burgess, 2025 |
| GHK-Cu | About 30 controlled topical studies | Formulation concentration, parts per million up to a few percent, over 8–12 weeks. No injectable dose has been published | Topical | Pickart & Margolina, 2018 |
| Thymosin alpha-1 | Phase 3 (n=552, 361 and 316) | 1.6 mg — twice weekly for hepatitis, twice daily for sepsis | Subcutaneous | Ciancio et al., 2012; Wu et al., 2013 |
| Hexarelin | Human dose-response and a 16-week study | 0.5 to 2 µg/kg acutely; 1.5 µg/kg twice daily for 16 weeks | Intravenous; subcutaneous | Imbimbo et al., 1994; Rahim et al., 1998 |
| AOD-9604 | Six trials, about 900 participants | 25–400 µg/kg intravenously; 0.25 to 54 mg orally | Intravenous; oral | Stier et al., 2013 |
| Glutathione | Randomized oral and intravenous trials | 250–1,000 mg/day orally; 600–1,400 mg intravenously | Oral; intravenous | Richie et al., 2015; Hauser et al., 2009 |
| Semax | Russian stroke reports (n=30 and 110) | 12 mg/day (moderate) and 18 mg/day (severe stroke) | Not stated in the record | Gusev et al., 1997 |
| Selank | Registered label; trials state no dose | 0.15% nasal solution, 1.5 mg per mL. The trials publish no amount | Intranasal | Russian registered instruction |
| MOTS-c | Mouse only | 0.5 to 15 mg/kg per day | Intraperitoneal | Lee et al., 2015; Reynolds et al., 2021 |
| Adipotide | Primate study; Phase 1 terminated at n=4 | 0.43 mg/kg daily for 28 days in macaques; 0.03 mg/kg human starting dose | Subcutaneous | Barnhart et al., 2011; NCT01262664 |
| 5-Amino-1MQ | Mouse only | 20 mg/kg per injection, three times daily, 11 days | Subcutaneous | Neelakantan et al., 2018 |
| Epithalon | Cell culture and mice only | 0.05 µg/mL in culture; 1 µg per mouse. The human data is Epithalamin | Culture medium; subcutaneous | Khavinson et al., 2003; Anisimov et al., 2002 |
| KPV | Mouse and cell culture only | 10 nM in culture; 100 µM in mouse drinking water | Oral, in the water supply | Dalmasso et al., 2008 |
A row is only as strong as its evidence column. Read that column first. A Phase 3 figure and a mouse figure look identical on a chart, and they are not the same kind of fact.
Which peptides have a dose from a human trial?
Thirteen rows. The incretin compounds — semaglutide, tirzepatide, retatrutide and cagrilintide — all have registered trials with published protocols. So do tesamorelin, bremelanotide, thymosin alpha-1, ipamorelin, CJC-1295, hexarelin, AOD-9604, glutathione and Semax.
That is the whole list, and it is shorter than the peptide market implies. Most of what is sold as a research compound has never been given to a person in a controlled study, so there is no human dose to report for it.
- Approved products. Semaglutide, tirzepatide, tesamorelin and bremelanotide have labels. A label is a dose that a regulator reviewed.
- Trial-only doses. Retatrutide, cagrilintide and hexarelin have protocols but no approval. The dose exists; the product does not.
- Failed or narrow trials. Ipamorelin's one human trial missed its endpoint, and AOD-9604's largest trial did not separate from placebo. The doses are still real. The results were negative.
Even inside that list, the dose is often a tolerability finding rather than an optimum. CJC-1295's ascending-dose trials are the clearest example.
Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults. [It] was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg.
Teichman et al., Journal of Clinical Endocrinology and Metabolism, 2006“Well tolerated” is not the same claim as “effective at.” A chart that prints 60 µg/kg without that sentence has changed what the study said.
Why do some rows say there is no dose?
Because nobody has run the study. BPC-157 is the clearest case. It is one of the most-searched compounds in this field, and its entire human record is two small pilot reports, neither designed to find a dose.
MOTS-c has never been given to a person at all. Neither has KPV, nor 5-amino-1MQ. Injectable GHK-Cu has zero published randomized trials, even though topical GHK-Cu has about 30. Epithalon's human record belongs to a different substance. We publish the gap because the gap is the answer.
Two rows are stranger than empty. Selank has a national registration and a printed strength, and the trials it is famous for publish no amount. Adipotide has a human starting dose sitting in a trial registry, from a study that enrolled four people and stopped.
Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce.
Mendias & Awan, Sports Medicine, 2026Charts agree with each other for the wrong reason. Search any of these compounds and you will find a dozen charts carrying the same number. Trace the number back and the chain ends at a forum post, not a paper. Repetition looks like consensus from the outside. It is not evidence, and a page that repeats it inherits nothing but the confidence.
Research compounds, with the paperwork
Third-party tested research compounds, each shipped with a batch-matched certificate of analysis showing HPLC purity and mass-spec identity — the documentation this site argues you should hold any supplier to.
Can an animal dose be converted to a human dose?
Not by the method most charts use. The common approach takes a rodent figure in milligrams per kilogram and multiplies it by human body weight. That is not how interspecies translation works.
Small animals run much higher metabolic rates per unit of mass. The FDA's guidance on first-in-human starting doses converts by body surface area instead, dividing a mouse dose by 12.3 and a rat dose by 6.2.
Even done correctly, the output is not a dose. It is the opening rung of a Phase 1 safety study, taken from the highest animal dose that caused no adverse effect, and a further safety factor is applied on top of it.
A dose is not a volume
Two different questions get mixed together constantly. The first is what amount a study administered. That is what this chart answers, and for many compounds the answer is nothing.
The second is arithmetic: given a vial strength and a volume of diluent, how many syringe units hold a given amount. That question always has an answer, and the peptide calculator does it in one step. Which syringe those units belong to is a third question, and the routes guide covers the calibration.
The trap is that easy arithmetic makes an unsourced number feel solid. A calculator will convert any figure you type perfectly well, including one that came from nowhere. Check where the figure came from before you convert it.
How to read a row on this chart
Four things decide what a row is worth, and none of them is the milligram figure itself.
- Species. A mouse row and a Phase 3 row are different kinds of claim. The chart labels every one.
- Route. Intraperitoneal, intravesical and topical all appear here. None of them is interchangeable with a subcutaneous injection.
- Design. A dose-finding trial sets a dose. A pilot report does not, even when it is in humans.
- Sample size. Two participants and 2,539 participants both produce a number. Only one of them produces a range you can trust.
Every compound name in the chart links to its own page, which carries the full protocol, the sample size and the reference list. Two more sit outside the table: the GLOW blend, where three constituents were studied separately and the blend never was, and CJC-1295 with ipamorelin, where two compounds with separate human doses are sold in one vial.
The reconstitution guide covers the step between a vial and a solution, and half-life explains why dosing intervals differ so much across this chart.
Research compounds, with the paperwork
Third-party tested research compounds, each shipped with a batch-matched certificate of analysis showing HPLC purity and mass-spec identity — the documentation this site argues you should hold any supplier to.
What to know now
- Thirteen rows on this chart carry a human trial dose. Everything else is animal work, a pilot, a label, or nothing at all.
- The largest trials here are semaglutide's STEP-1 at 1,961 participants and tirzepatide's SURMOUNT-1 at 2,539.
- BPC-157's entire human record is two pilot reports, one with 12 participants and one with 2.
- Injectable GHK-Cu has no published randomized trial, so no injectable dose exists to report.
- Body-weight scaling from a rodent dose is the wrong conversion. Surface-area scaling divides a mouse dose by 12.3, and still only yields a Phase 1 start.
- Vial-to-syringe arithmetic is a separate question with a real answer. That is what the calculator is for.
What we're watching
Registered dose-finding trials are what would change this chart. A Phase 1 for MOTS-c or an Achilles-tendinopathy Phase 2 for BPC-157 would each turn an empty row into a real one. Retatrutide's Phase 3 program will also replace a Phase 2 protocol with a registration protocol, and those rarely match exactly.
We revise rows when a trial publishes, not when a chart elsewhere changes.
Frequently asked questions
Is there a standard peptide dosage chart?
No. There is no standard because most of these compounds have never had a dose-finding trial. The charts that circulate agree with each other because they copy each other, not because a study underwrites them.
Which peptides have a dose from a human trial?
Thirteen: semaglutide, tirzepatide, retatrutide, cagrilintide, tesamorelin, bremelanotide, thymosin alpha-1, ipamorelin, CJC-1295, hexarelin, AOD-9604, glutathione and Semax. Everything else is animal work, a pilot report, or nothing.
Why do some rows on this chart say there is no dose?
Because no study has administered one to a person. MOTS-c, KPV, 5-amino-1MQ and injectable GHK-Cu are the clearest cases, and BPC-157 has only two small pilot reports. We publish the empty row rather than filling it with a number nobody measured.
Can an animal dose be converted into a human dose?
Not by multiplying milligrams per kilogram by body weight. Interspecies scaling goes by body surface area, and even done correctly it yields a Phase 1 starting dose, not a treatment dose.
Does a dosage chart tell you how much liquid to draw?
No. That is a separate calculation from the vial strength and the volume of diluent used, and it is pure arithmetic. Our peptide calculator does that part.
References
- Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet, 398(10317), 2160–2172. https://doi.org/10.1016/S0140-6736(21)01751-7
- Falutz, J., Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/nejmoa072375
- U.S. Food and Drug Administration. (2019). Vyleesi (bremelanotide injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
- Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
- Beck, D. E., Sweeney, W. B., McCarter, M. D., & the Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
- Lee, E., Walker, C., & Ayadi, B. (2024). Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine, 30(10), 12–17. PMID 39325560
- Lee, E., & Burgess, K. (2025). Safety of intravenous infusion of BPC-157 in humans: A pilot study. Alternative Therapies in Health and Medicine, 31(5), 20–24. PMID 40131143
- Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987. https://doi.org/10.3390/ijms19071987
- Lee, C., Zeng, J., Drew, B. G., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454. https://doi.org/10.1016/j.cmet.2015.02.009
- Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12, 470. https://doi.org/10.1038/s41467-020-20790-0
- Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. https://doi.org/10.1007/s40279-026-02437-0
Every dose in the chart above comes from one of these sources. Where a compound has no source, it has no figure.